StockData
Evotec SE logo

Evotec SE (EVO) stock

EVONasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as EVOTF
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 8, 2026Score 4/30
$1.58−0.08 (-4.82%)

Close on Nov 13, 2026Market cap $561.78MP/E –Yield –

Earnings

Evotec's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
–
Not yet scheduled
Revenue, Q4 FY2025
€253.30M
EPS, Q4 FY2025
–
Latest guidance
Issued
Apr 8, 2026 · 2 items

Quarterly results

Revenue and earnings per share from each of Evotec's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q4 FY2025ended Dec 31, 2025Apr 8, 2026during market hours€253.30M––Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Evotec's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
Group revenuesGAAPFY2026700 – 780–NewApr 8, 2026
Adjusted Group EBITDAnon-GAAPFY20260 – 40–NewApr 8, 2026

Guidance history

Every forecast Evotec put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Apr 8, 2026Adjusted Group EBITDAFY20260 – 40New
Apr 8, 2026Group revenuesFY2026700 – 780New

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Evotec filed with the SEC as exhibits to Form 8-K or 6-K

  1. 6-K
  2. 6-K
  3. 6-K
  4. 6-K
  5. 6-K
  6. 6-K
  7. 6-K
  8. 6-K
  9. 6-K
  10. 6-K
  11. 6-K
  12. 6-K
  13. 6-K
  14. 6-K
  15. 6-K

See a number that looks wrong?